Pharmacogenetics of Coumarin Anticoagulant Therapy
- 25 June 2015
- book chapter
- Published by Springer Nature
- p. 307-328
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parametersEuropean Journal of Clinical Pharmacology, 2010
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interactionEuropean Journal of Clinical Pharmacology, 2007
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Warfarin: almost 60 years old and still causing problemsBritish Journal of Clinical Pharmacology, 2006